Teleflex/$TFX
1D1W1MYTD1Y5YMAX
Capital at risk
About Teleflex
Teleflex Inc is a provider of medical technology products focused on enhancing clinical benefits, improving patient and provider safety and reducing total procedural costs. It designs, develops, manufactures and supply medical devices used by hospitals and healthcare providers supporting high-acuity emergent procedures. The company has three reportable segments: Americas, EMEA (Europe, the Middle East and Africa) and Asia (Asia Pacific). It derives maximum revenue from Americas. Its products includes: Anaesthesia, Emergency Medicine, Interventional Cardiology/Radiology, Interventional Urology - UroLift System, Surgery, Urology, and Vascular Access.
- Ticker
- $TFX
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 15,500
- Headquarters
- Wayne, United States
- Website
- www.teleflex.com
Teleflex Metrics
BasicAdvanced
$5.4B
-
-$23.41
0.81
$1.02
1.07%
Price and volume
Market cap
$5.4B
Beta
0.81
52-week high
$145.00
52-week low
$100.18
Average daily volume
725K
Dividend rate
$1.02
Financial strength
Current ratio
2.604
Quick ratio
0.956
Long term debt to equity
0.976
Total debt to equity
0.989
Interest coverage (TTM)
1.74%
Profitability
EBITDA (TTM)
420.983
Gross margin (TTM)
55.11%
Net profit margin (TTM)
-45.76%
Operating margin (TTM)
8.79%
Effective tax rate (TTM)
60.58%
Revenue per employee (TTM)
$150,000
Management effectiveness
Return on assets (TTM)
1.75%
Return on equity (TTM)
-0.70%
Valuation
Price to revenue (TTM)
2.49
Price to book
1.86
Price to tangible book (TTM)
-6.45
Price to free cash flow (TTM)
17.163
Free cash flow yield (TTM)
5.83%
Free cash flow per share (TTM)
7.422
Dividend yield (TTM)
0.80%
Forward dividend yield
1.07%
Growth
Revenue change (TTM)
110.94%
Earnings per share change (TTM)
-660.80%
3-year revenue growth (CAGR)
-8.04%
10-year revenue growth (CAGR)
2.18%
3-year earnings per share growth (CAGR)
44.27%
10-year earnings per share growth (CAGR)
15.31%
What the Analysts think about Teleflex
Analyst ratings (Buy, Hold, Sell) for Teleflex stock.
Analyst projections of the future price of Teleflex stock.
Bulls say / Bears say
The OEM divestiture has released cash for balance-sheet repair and shareholder returns: Teleflex used proceeds to repay about $700 million of debt and fund substantial buybacks. Lower interest expense and a smaller share count helped lift 2026 adjusted EPS guidance to $6.90-$7.20 despite the weaker revenue outlook. (Teleflex, MarketScreener)
Teleflex has added a differentiated growth option with FDA approval for EZPLAZ, the first freeze-dried plasma product licensed in the US. Its shelf-stable format could serve ambulance, hospital and military trauma settings where conventional frozen plasma is difficult to store or prepare. (Morningstar)
The underlying Vascular and Surgical businesses delivered strong first-half performance, while management is targeting a roughly 23% steady-state adjusted operating margin. A restructuring programme expected to generate about $50 million of annual pre-tax savings by mid-2028 could add operating leverage once separation costs and integration work fade. (The Motley Fool, Teleflex)
The BIOTRONIK Vascular Intervention integration is taking longer than expected, with order-to-cash, distributor and sales-force problems weighing on performance. Teleflex cut 2026 pro forma adjusted constant-currency revenue growth guidance to 3.5%-4.5% from 4.5%-5.5%, and the low end assumes no Interventional revenue improvement for the rest of the year. (The Motley Fool, Teleflex)
Profitability is under pressure before the promised recovery: second-quarter adjusted gross margin fell to 61.7%, while adjusted operating margin was 19.6%. Tariffs and the acquired business's lower margin profile are the main stated causes, leaving a sizeable gap to the 23% steady-state target. (The Motley Fool, EveryTicker)
The portfolio reset is still creating execution and cost risk: the Acute Care and Interventional Urology sale remained subject to regulatory approval, while separation costs reached $59.2 million in the first half. Until the transaction closes and stranded costs are removed, reported earnings can remain well below the business's intended steady-state level. (MetaTrader, Teleflex)
Data summarised monthly by Lightyear AI. Last updated on 28 Sept 2026.
Teleflex Financial Performance
Revenues and expenses
Teleflex Earnings Performance
Company profitability
Upcoming events
No upcoming events
Teleflex News
AllArticlesVideos
Teleflex Announces Latest Peer-Reviewed Study Demonstrates a Significant Reduction in CLABSI Risk with Arrowg+ard™ Technology
Business Wire2 days ago
Teleflex Appoints Veteran Medical Technology Executive Sean M. Salmon to Teleflex Board of Directors
Business Wire3 weeks ago
Teleflex Features Innovative Dynetic™-35 Balloon-Expandable Cobalt Chromium Stent System at CIRSE 2026
Business Wire4 weeks ago
Funds containing Teleflex
AllUSDGBPEUR
Fund name | Fund size | $TFX weighting |
|---|---|---|
iShares S&P SmallCap 600$IDP6 | $3.2B | 0.31% |
iShares S&P Small Cap 600£ISP6 | £2.4B | 0.30% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.14% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | £2.4B | 0.14% |
iShares MSCI World Small Cap$WSML | $9B | 0.05% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.